Objective: To investigate the clinical features and side effects, with regard to glucocorticoid-induced ocular hypertension, glaucoma or cataract in children with primary nephrotic syndrome. Methods: Clinical data were collected and analyzed from 71 cases of primary nephrotic syndrome with glucocorticoid-induced ocular hypertension, glaucoma or cataract from Jun. 2014 to Jun. 2016. These children were hospitalized in Peking University First Hospital. Results: Totally 1 580 children with primary nephrotic syndrome were collected, glucocorticoid-induced complications in eyes were found in 71 cases, and the incidence was 4.5%. There were 66 cases with ocular hypertension, 2 cases with glucocorticoid glaucoma, 2 cases with glucocorticoid glaucoma combined with cataract, 1 case with high intraocular pressure combined with cataract. There were 41 boys and 30 girls with eye-related side effects caused by glucocorticoid. The average age of onset of glucocorticoid-induced eye adverse reactions in children with primary nephrotic syndrome in our research were 8 (2, 16) years. The average duration or interval time from glucocorticoid medication use to eye adverse effects was 157 (6, 420) days. No statistical significance was found in intraocular pressure between different genders, types of glucocorticoid, different route of glucocorticoid and whether methylprednisolone pulse treatment (P>0.05). There was no significant correlation between age, body mass index, blood pressure, cumulative dosage, duration time of glucocorticoid, mean daily dosage and glucocorticoid-induced ocular hypertension (P>0.05). The ocular hypertension was controlled after treatment. Conclusion: Children with nephrotic syndrome after treatment of glucocorticoid are susceptible to ocular complications, and the occurrence of ocular hypertension is closely related to glucocorticoid susceptibility of the nephrotic children. Regular eye monitor is indispensable for the children suffering from primary nephrotic syndrome.
ZHAO Yun
,
SU Bai-ge
,
XIAO Hui-jie
,
ZHANG Hong-wen
,
LIU Xiao-yu
,
WANG Fang
,
DING Jie
. Clinical characteristics of glucocorticoid-induced eye adverse reactions in children with primary nephrotic syndrome[J]. Journal of Peking University(Health Sciences), 2017
, 49(5)
: 794
-797
.
DOI: 10.3969/j.issn.1671-167X.2017.05.009
[1] 胡亚美, 江载芳. 诸福棠实用儿科学[M]. 8版. 北京: 人民卫生出版社, 2015: 1729, 1783.
[2] Rüfer F, Uthoff D. Symptoms and therapy for steroid glaucoma [J]. Klin Monbl Augenheilkd, 2013, 230(7): 692-696.
[3] Dibas A, Yorio T. Glucocorticoid therapy and ocular hypertension [J]. Eur J Pharmacol, 2016(787): 57-71.
[4] 中华医学会儿科学分会肾脏病学组. 小儿肾小球疾病的临床分类、诊断及治疗[J]. 中华儿科杂志, 2001, 39(12): 746-749.
[5] 李凤鸣. 中华眼科学[M]. 北京: 人民卫生出版社, 2006: 1473, 1583, 1772.
[6] Zode GS, Sharma AB, Lin X, et al. Ocular-specific ER stress reduction rescues glaucoma in murine glucocorticoid-induced glaucoma [J]. J Clin Invest, 2014, 124(5): 1956-1965.
[7] Skuta GL, Morgan RK. Corticosteroid induced glaucoma [M]//Ritch R, Shields MR, Krupin T. The glaucoma. St. Louis: Mostly, 1996: 1177-1188.
[8] Bermudez JY,Webber HC,Brown B,et al. A comparison of gene expression profiles between glucocorticoid responder and non-responder bovine trabecular meshwork cells using RNA sequencing [J/OL]. PLoS One, 2017, 12(1): e0169671.
[9] Wang XQ, Duan ZX, He XG, et al. Clinical relevance of the glucocorticoid receptor gene polymorphisms in glucocorticoid-induced ocular hypertension and primary open angle glaucoma [J]. Int J Ophthalmol, 2015, 1(18): 169-173.
[10] 王玲, 陈慧, 谢青, 等. 103例糖皮质激素性青光眼的研究[J]. 现代预防医学, 2011, 38(21): 4562-4564.
[11] Jeppesen P, Krag S. Steroid treatment and risk of glaucoma [J]. Ugeskr Laeger, 2015, 177(34): 1620-1623.
[12] Jain A, Wordinger RJ, Yorio T, et al. Role of the alternatively spliced glucocorticoid receptor isoform GRβ in steroid responsiveness and glaucoma [J]. J Ocul Pharmacol Ther, 2014, 30 (2-3): 121-127.
[13] Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data [J]. Ann Rheum Dis, 2006, 65(3): 285-293.
[14] 苗静, 徐虹, 沈茜, 等. 原发肾病综合征患儿糖皮质激素治疗致眼科不良反应分析[J]. 临床儿科杂志, 2013, 31(4): 335-338.